Latest Doxylamine Stories

Prescription Treatment Now Available in Pharmacies for Nearly Three Million Pregnant Women Who Suffer From NVP ROSEMONT, Pa., May 21, 2013 /PRNewswire/ -- Duchesnay USA, the first pharmaceutical company dedicated to the health of pregnant women, announces the U.S. market introduction of Diclegis(®) (doxylamine succinate 10mg and pyridoxine hydrochloride -vitamin B(6)- 10mg), now available in pharmacies across the country. Diclegis was recently approved by the U.S. Food and Drug...

redOrbit Staff & Wire Reports - Your Universe Online A drug pulled from pharmacies three decades ago following accusations that it was responsible for causing birth defects has now become the only US Food and Drug Administration (FDA)-approved treatment for morning sickness, according to various media reports published Tuesday. The medication is known as Diclegis, and according to MedPageToday Staff Writer Nancy Walsh it is a combination of vitamin B6 and an antihistamine. More...

BLAINVILLE, QC, April 9, 2013 /CNW Telbec/ - Following the US approval of its morning sickness medication Diclegis by the US Food and Drug Administration (FDA), the Canadian pharmaceutical company Duchesnay Inc. is proud to announce that this approval sets the obstetric medicine specialty company for international expansion. Diclegis has been available in Canada under the trade name Diclectin® for more than 30 years as the only prescription drug specifically indicated and...

In the news release, FDA Approves Duchesnay USA's Diclegis® for Treatment of Nausea and Vomiting of Pregnancy (NVP), issued 08-Apr-2013 by Duchesnay USA over PR Newswire, we are advised by the company that Laney Cohen's phone number should read "(212) 508-9643" rather than "(215) 508-9643" as originally issued inadvertently. The complete, corrected release follows: FDA Approves Duchesnay USA's Diclegis® for Treatment of Nausea and Vomiting of Pregnancy (NVP) Diclegis becomes only...

Diclegis becomes only FDA-approved treatment for "morning sickness" in decades ROSEMONT, Pa., April 8, 2013 /PRNewswire/ -- Duchesnay USA today announced that the Food and Drug Administration (FDA) has granted approval for Diclegis(®) (doxylamine succinate 10mg, pyridoxine hydrochloride 10mg) delayed-release tablets for the treatment of nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management.(i) It is the only FDA-approved treatment for NVP,...

Early use of Diclectin(®) reduces the severity of nausea and vomiting of pregnancy (NVP) symptoms in pregnant women who had severe NVP in a previous pregnancy BLAINVILLE, QC (CANADA), Feb. 14, 2013 /PRNewswire/ - Duchesnay Inc. announced results from a new study concluding that pre-emptive use of Diclectin(®) (a delayed-release combination of 10 mg doxylamine and 10 mg pyridoxine) is effective in reducing symptoms of severe NVP in patients at high risk for recurrence of severe...

To view the B-Roll Video, please enter the following address in your web browser. http://cnw.pathfireondemand.com/viewpackage.action?packageid=387 MONTREAL, Sept. 16 /PRNewswire/ - In the latest issue of the American Journal of Obstetrics and Gynecology, a group of American and Canadian researchers report on the effectiveness of Diclectin(R) (the delayed-release formulation of doxylamine and vitamin B6) for morning sickness. Morning sickness affects up to 80% of pregnant women, and many...